Magnetic Resonance Image Guided Brachytherapy

Seminars in Radiation Oncology

Volumn 24, Issue 3, 2014, Pages 181-191

  Tanderup, Kari ^a,b   Viswanathan, Akila N ^c   Kirisits, Christian ^d   Frank, Steven J ^e  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYTHERAPY; CANCER RADIOTHERAPY; CLINICAL PRACTICE; DOSE RESPONSE; GYNECOLOGIC CANCER; HUMAN; MEDICAL DECISION MAKING; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION RESPONSE; RADIATION SAFETY; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME; UTERINE CERVIX CANCER; COMPUTER ASSISTED RADIOTHERAPY; FEMALE; IMAGE GUIDED RADIOTHERAPY; INTERVENTIONAL MAGNETIC RESONANCE IMAGING; MALE; ONCOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; UTERINE CERVICAL NEOPLASMS;

BRACHYTHERAPY; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; MALE; PROSTATIC NEOPLASMS; RADIATION ONCOLOGY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; UTERINE CERVICAL NEOPLASMS;

EID: 84902136361     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2014.02.007     Document Type: Review

References (78)

1. Pötter R., Dimopoulos J., Georg P., et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol 2007, 83(2):148-155.
2. Tanderup K., Nielsen S.K., Nyvang G.B., et al. From point A to the sculpted pear: MR image guidance significantly improves tumour dose and sparing of organs at risk in brachytherapy of cervical cancer. Radiother Oncol 2010, 94(2):173-180.
3. Jürgenliemk-Schulz I.M., Tersteeg R.J., Roesink J.M., et al. MRI-guided treatment-planning optimisation in intracavitary or combined intracavitary/interstitial PDR brachytherapy using tandem ovoid applicators in locally advanced cervical cancer. Radiother Oncol 2009, 93(2):322-330.
4. Pötter R., Georg P., Dimopoulos J.C., et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 2011, 100(1):116-123.
5. Lindegaard J.C., Fokdal L.U., Nielsen S.K., et al. MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective. Acta Oncol 2013, 52(7):1510-1519.
6. Haie-Meder C., Pötter R., van Limbergen E., et al. Recommendations from Gynaecological (GYN) GEC-ESTRO working group (I): Concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005, 74(3):235-245.
7. Pötter R., Haie-Meder C., van Limbergen E., et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006, 78(1):67-77.
8. Hellebust T.P., Kirisits C., Berger D., et al. Recommendations from Gynaecological (GYN) GEC-ESTRO working group: Considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy. Radiother Oncol 2010, 96(2):153-160.
9. Dimopoulos J.C., Petrow P., Tanderup K., et al. Recommendations from Gynaecological (GYN) GEC-ESTRO working group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiother Oncol 2012, 103(1):113-122.
10. Viswanathan A.N., Beriwal S., De Los Santos J.F., et al. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II: High-dose-rate brachytherapy. Brachytherapy 2012, 11(1):47-52.
11. Viswanathan A.N., Thomadsen B. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: General principles. Brachytherapy 2012, 11(1):33-46.
12. Takiar V., Pugh T.J., Swanson D., et al. MRI-based sector analysis enhances prostate palladium-103 brachytherapy quality assurance in a phase II prospective trial of men with intermediate-risk localized prostate cancer. Brachytherapy 2014, 13(1):68-74.
13. McLaughlin P.W., Troyer S., Berri S., et al. Functional anatomy of the prostate: Implications for treatment planning. Int J Radiat Oncol Biol Phys 2005, 63(2):479-491.
14. Register S.P., Kudchadker R.J., Levy L.B., et al. An MRI-based dose-reponse analysis of urinary sphincter dose and urinary morbidity after brachytherapy for prostate cancer in a phase II prospective trial. Brachytherapy 2013, 12(3):210-216.
15. Wang J.Z., Mayr N.A., Zhang D., et al. Sequential magnetic resonance imaging of cervical cancer: The predictive value of absolute tumor volume and regression ratio measured before, during, and after radiation therapy. Cancer 2010, 116(21):5093-5101.
16. Viswanathan A.N., Szymonifka J., Tempany-Afdhal C.M., et al. A prospective trial of real-time magnetic resonance-guided catheter placement in interstitial gynecologic brachytherapy. Brachytherapy 2013, 12(3):240-247.
17. Davidson M.T., Yuen J., D[U+05F3]Souza D.P., et al. Optimization of high-dose-rate cervix brachytherapy applicator placement: The benefits of intraoperative ultrasound guidance. Brachytherapy 2008, 7(3):248-253.
18. Fokdal L., Tanderup K., Hokland S.B., et al. Clinical feasibility of combined intracavitary/interstitial brachytherapy in locally advanced cervical cancer employing MRI with a tandem/ring applicator in situ and virtual preplanning of the interstitial component. Radiother Oncol 2013, 107(1):63-68.
19. Viswanathan A.N., Creutzberg C.L., Craighead P., et al. International brachytherapy practice patterns: A survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys 2012, 82(1):250-255.
20. Viswanathan A.N., Dimopoulos J., Kirisits C., et al. Computed tomography versus magnetic resonance imaging-based contouring in cervical cancer brachytherapy: Results of a prospective trial and preliminary guidelines for standardized contours. Int J Radiat Oncol Biol Phys 2007, 68(2):491-498.
21. Mohamed S., Nielsen S.K., Fokdal L.U., et al. Feasibility of applying a single treatment plan for both fractions in PDR image guided brachytherapy in cervix cancer. Radiother Oncol 2013, 107(1):32-38.
22. Kirisits C., Lang S., Dimopoulos J., et al. Uncertainties when using only one MRI-based treatment plan for subsequent high-dose-rate tandem and ring applications in brachytherapy of cervix cancer. Radiother Oncol 2006, 81(3):269-275.
23. Lang S., Nesvacil N., Kirisits C., et al. Uncertainty analysis for 3D image-based cervix cancer brachytherapy by repetitive MR imaging: Assessment of DVH-variations between two HDR fractions within one applicator insertion and their clinical relevance. Radiother Oncol 2013, 107(1):26-31.
24. Nesvacil N., Tanderup K., Hellebust T.P., et al. A multicentre comparison of the dosimetric impact of inter- and intra-fractional anatomical variations in fractionated cervix cancer brachytherapy. Radiother Oncol 2013, 107(1):20-25.
25. Nesvacil N., Pötter R., Sturdza A., et al. Adaptive image guided brachytherapy for cervical cancer: A combined MRI-/CT-planning technique with MRI only at first fraction. Radiother Oncol 2013, 107(1):75-81.
26. Haider M.A., van der Kwast T.H., Tanguay J., et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. Am J Roentgenol 2007, 189(2):323-328.
27. D[U+05F3]Amico A.V., Cormack R., Tempany C.M., et al. Real-time magnetic resonance image-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1998, 42(3):507-515.
28. Menard C., Susil R.C., Choyke P., et al. MRI-guided HDR prostate brachytherapy in standard 1.5T scanner. Int J Radiat Oncol Biol Phys 2004, 59(5):1414-1423.
29. Hoskin P.J., Colombo A., Henry A., et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update. Radiother Oncol 2013, 107(3):325-332.
30. Moerland M.A., Wijrdeman H.K., Beersma R., et al. Evaluation of permanent I-125 prostate implants using radiography and magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1997, 37(4):927-933.
31. Ohashi T., Momma T., Yamashita S., et al. Impact of MRI-based postimplant dosimetric assessment in prostate brachytherapy using contrast-enhanced T1-weighted images. Brachytherapy 2012, 11(6):468-475.
32. Nguyen P.L., Chen M.H., Zhang Y., et al. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: Implications for focal therapy. J Urol 2012, 188(4):1151-1156.
33. Frank S.J., Stafford R.J., Bankson J.A., et al. A novel MRI marker for prostate brachytherapy. Int J Radiat Oncol Biol Phys 2008, 71(1):5-8.
34. Polo A., Cattani F., Vavassori A., et al. MR and CT image fusion for postimplant analysis in permanent prostate seed implants. Int J Radiat Oncol Biol Phys 2004, 60(5):1572-1579.
35. Lichy M.P., Wietek B.M., Mugler J.P., et al. Magnetic resonance imaging of the body trunk using a single-slab, 3-dimensional, T2-weighted turbo-spin-echo sequence with high sampling efficiency (SPACE) for high spatial resolution imaging: Initial clinical experiences. Invest Radiol 2005, 40(12):754-760.
36. Pugh T.J., Frank S.J., Achim M., et al. Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy. Brachytherapy 2013, 12(3):204-209.
37. Albert J.M., Swanson D.A., Pugh T.J., et al. Magnetic resonance imaging-based treatment planning for prostate brachytherapy. Brachytherapy 2013, 12(1):30-37.
38. Halle C., Andersen E., Lando M., et al. Hypoxia-induced gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-enhanced MRI. Cancer Res 2012, 72(20):5285-5295.
39. Haack S., Pedersen E.M., Jespersen S.N., et al. Apparent diffusion coefficients in GEC ESTRO target volumes for image guided adaptive brachytherapy of locally advanced cervical cancer. Acta Oncol 2010, 49(7):978-983.
40. Esthappan J., Ma D.J., Narra V.R., et al. Comparison of apparent diffusion coefficient maps to T2-weighted images for target delineation in cervix cancer brachytherapy. J Contemp Brachytherapy 2011, 3(4):193-198.
41. Barentsz J.O., Richenberg J., Clements R., et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012, 22(4):746-757.
42. Bauman G., Haider M., Van der Heide U.A., et al. Boosting imaging defined dominant prostatic tumors: A systematic review. Radiother Oncol 2013, 107(3):274-281.
43. Haider M.A., Chung P., Sweet J., et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008, 70(2):425-430.
44. Groenendaal G., Borren A., Moman M.R., et al. Pathologic validation of a model based on diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging for tumor delineation in the prostate peripheral zone. Int J Radiat Oncol Biol Phys 2012, 82(3):e537-e544.
45. Kim Y., Muruganandham M., Modrick J.M., et al. Evaluation of artifacts and distortions of titanium applicators on 3.0-Tesla MRI: Feasibility of titanium applicators in MRI-guided brachytherapy for gynecological cancer. Int J Radiat Oncol Biol Phys 2011, 80(3):947-955.
46. Haack S., Nielsen S.K., Lindegaard J.C., et al. Applicator reconstruction in MRI 3D image-based dose planning of brachytherapy for cervical cancer. Radiother Oncol 2009, 91(2):187-193.
47. Hu Y., Esthappan J., Mutic S., et al. Improve definition of titanium tandems in MR-guided high dose rate brachytherapy for cervical cancer using proton density weighted MRI. Radiat Oncol 2013, 8:16.
48. Kapur T., Egger J., Damato A., et al. 3-T MR-guided brachytherapy for gynecologic malignancies. Magn Reson Imaging 2012, 30(9):1279-1290.
49. de Leeuw H., Seevinck P.R., Bakker C.J. Center-out radial sampling with off-resonant reconstruction for efficient and accurate localization of punctate and elongated paramagnetic structures. Magn Reson Med 2013, 69(6):1611-1622.
50. Schindel J., Muruganandham M., Pigge F.C., et al. Magnetic resonance imaging (MRI) markers for MRI-guided high-dose-rate brachytherapy: Novel marker-flange for cervical cancer and marker catheters for prostate cancer. Int J Radiat Oncol Biol Phys 2013, 86(2):387-393.
51. Wills R., Lowe G., Inchley D., et al. Applicator reconstruction for HDR cervix treatment planning using images from 0.35T open MR scanner. Radiother Oncol 2010, 94(3):346-352.
52. Perez-Calatayud J., Kuipers F., Ballester F., et al. Exclusive MRI-based tandem and colpostats reconstruction in gynaecological brachytherapy treatment planning. Radiother Oncol 2009, 91(2):181-186.
53. Frank S.J., Tailor R.C., Kudchadker R.J., et al. Anisotropy characterization of I-125 seed with attached encapsulated cobalt chloride complex contrast agent markers for MRI-based prostate brachytherapy. Med Dosim 2011, 36(2):200-205.
54. Stanescu T., Wachowicz K., Jaffray D.A. Characterization of tissue magnetic susceptibility-induced distortions for MRIgRT. Med Phys 2012, 39(12):7185-7193.
55. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 1995, 22(2):209-234.
56. Beaulieu L., Carlsson T.A., Carrier J.F., et al. Report of the Task Group 186 on model-based dose calculation methods in brachytherapy beyond the TG-43 formalism: Current status and recommendations for clinical implementation. Med Phys 2012, 39(10):6208-6236.
57. Tanderup K., Nesvacil N., Pötter R., et al. Uncertainties in image guided adaptive cervix cancer brachytherapy: Impact on planning and prescription. Radiother Oncol 2013, 107(1):1-5.
58. Hellebust T.P., Tanderup K., Lervag C., et al. Dosimetric impact of interobserver variability in MRI-based delineation for cervical cancer brachytherapy. Radiother Oncol 2013, 107(1):13-19.
59. Petric P., Hudej R., Rogelj P., et al. Uncertainties of target volume delineation in MRI guided adaptive brachytherapy of cervix cancer: A multi-institutional study. Radiother Oncol 2013, 107(1):6-12.
60. Berger D., Dimopoulos J., Pötter R., et al. Direct reconstruction of the Vienna applicator on MR images. Radiother Oncol 2009, 93(2):347-351.
61. de Brabandere M., Hoskin P., Haustermans K., et al. Prostate post-implant dosimetry: Interobserver variability in seed localisation, contouring and fusion. Radiother Oncol 2012, 104(2):192-198.
62. Andersen E.S., Noe K.O., Sorensen T.S., et al. Simple DVH parameter addition as compared to deformable registration for bladder dose accumulation in cervix cancer brachytherapy. Radiother Oncol 2013, 107(1):52-57.
63. Simnor T., Li S., Lowe G., et al. Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer. Radiother Oncol 2009, 93(2):253-258.
64. Jamema S.V., Mahantshetty U., Tanderup K., et al. Inter-application variation of dose and spatial location of D2cm3 volumes of OARs during MR image based cervix brachytherapy. Radiother Oncol 2013, 107(1):58-62.
65. Dimopoulos J.C., Kirisits C., Petric P., et al. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: Clinical feasibility and preliminary results. Int J Radiat Oncol Biol Phys 2006, 66(1):83-90.
66. Citrin D., Ning H., Guion P., et al. Inverse treatment planning based on MRI for HDR prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 61(4):1267-1275.
67. Nomden C.N., de Leeuw A.A., Roesink J.M., et al. Clinical outcome and dosimetric parameters of chemo-radiation including MRI guided adaptive brachytherapy with tandem-ovoid applicators for cervical cancer patients: A single institution experience. Radiother Oncol 2013, 107(1):69-74.
68. Mahantshetty U., Swamidas J., Khanna N., et al. Magnetic resonance image-based dose volume parameters and clinical outcome with high dose rate brachytherapy in cervical cancers-a validation of GYN GEC-ESTRO brachytherapy recommendations. Clin Oncol (R Coll Radiol) 2011, 23(5):376-377.
69. Chargari C., Magne N., Dumas I., et al. Physics contributions and clinical outcome with 3D-MRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients. Int J Radiat Oncol Biol Phys 2009, 74(1):133-139.
70. Dimopoulos J.C., Schmid M.P., Fidarova E., et al. Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: Dose-volume parameters and first clinical results. Int J Radiat Oncol Biol Phys 2012, 82(5):1880-1888.
71. Fokdal L., Tanderup K., Nielsen S.K., et al. Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept. Radiother Oncol 2011, 100(3):473-479.
72. Ares C., Popowski Y., Pampallona S., et al. Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: A sequential dose-escalation pilot study. Int J Radiat Oncol Biol Phys 2009, 75(3):656-663.
73. D[U+05F3]Amico A.V., Tempany C.M., Schultz D., et al. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate. Urology 2003, 62(6):1063-1067.
74. Nguyen P.L., Chen R.C., Clark J.A., et al. Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective phase II study. Brachytherapy 2009, 8(4):345-352.
75. Han K., Milosevic M., Fyles A., et al. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys 2013, 87(1):111-119.
76. Deutsch I., Zelefsky M.J., Zhang Z., et al. Comparison of PSA relapse-free survival in patients treated with ultra-high-dose IMRT versus combination HDR brachytherapy and IMRT. Brachytherapy 2010, 9(4):313-318.
77. van Elmpt W., De R.D., van der Salm A., et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol 2012, 104(1):67-71.
78. Berwouts D., Olteanu L.A., Duprez F., et al. Three-phase adaptive dose-painting-by-numbers for head-and-neck cancer: Initial results of the phase I clinical trial. Radiother Oncol 2013, 107(3):310-316.